These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 30070770

  • 1. Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
    Ambery C, Young G, Fuller T, Georgiou A, Ramsay D, Puri A, Daley-Yates P.
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):188-197. PubMed ID: 30070770
    [Abstract] [Full Text] [Related]

  • 2. Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
    Ambery C, Riddell K, Daley-Yates P.
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):399-407. PubMed ID: 27170445
    [Abstract] [Full Text] [Related]

  • 3. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.
    Crim C, Gotfried M, Spangenthal S, Watkins M, Emmett A, Crawford C, Baidoo C, Castro-Santamaria R.
    BMC Pulm Med; 2020 May 04; 20(1):119. PubMed ID: 32366249
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.
    Pharmacotherapy; 2015 Jun 04; 35(6):586-99. PubMed ID: 26059225
    [Abstract] [Full Text] [Related]

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 04; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
    Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.
    Int J Clin Pharmacol Ther; 2015 Sep 04; 53(9):753-64. PubMed ID: 26227101
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.
    Allen A, Murdoch RD, Bareille P, Burns O, Hughes S, Gupta A, Miller SR.
    Clin Pharmacol Drug Dev; 2016 May 04; 5(3):225-31. PubMed ID: 27163502
    [Abstract] [Full Text] [Related]

  • 8. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T.
    Int J Clin Pharmacol Ther; 2013 Aug 04; 51(8):660-71. PubMed ID: 23735179
    [Abstract] [Full Text] [Related]

  • 9. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
    Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S.
    Adv Ther; 2015 Feb 04; 32(2):157-71. PubMed ID: 25700806
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers.
    Norris V, Ambery C, Riley T.
    Clin Pharmacol Drug Dev; 2014 Jul 04; 3(4):305-13. PubMed ID: 27128837
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
    Mehta R, Moore A, Riddell K, Joshi S, Chan R.
    J Aerosol Med Pulm Drug Deliv; 2017 Oct 04; 30(5):332-338. PubMed ID: 28463040
    [Abstract] [Full Text] [Related]

  • 12. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.
    Allen A, Bareille PJ, Rousell VM.
    Clin Pharmacokinet; 2013 Jan 04; 52(1):37-42. PubMed ID: 23184737
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men.
    Ambery C, Young G, Fuller T, Lazaar AL, Pereira A, Hughes A, Ramsay D, van den Berg F, Daley-Yates P.
    Clin Pharmacol Drug Dev; 2018 Nov 04; 7(8):901-910. PubMed ID: 30230263
    [Abstract] [Full Text] [Related]

  • 14. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan 04; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 15. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 04; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M, Goldfrad C, Jacques L, Nishimura Y.
    Respir Med; 2016 Nov 04; 120():78-86. PubMed ID: 27817819
    [Abstract] [Full Text] [Related]

  • 17. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A, Davis A, Hardes K, Tombs L, Kempsford R.
    Clin Ther; 2012 Dec 04; 34(12):2316-32. PubMed ID: 23200625
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug 04; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 19. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.
    Clin Ther; 2014 Jun 01; 36(6):928-939.e1. PubMed ID: 24793536
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
    Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM.
    Respir Med; 2018 Aug 01; 141():111-120. PubMed ID: 30053956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.